GlaxoSmithKline has announced the purchase of 306,478 of its own ordinary shares as part of its ongoing buyback programme. This transaction, executed through Merrill Lynch International, is part of a ...

GlaxoSmithKline ( ($GB:GSK) ) just unveiled an update. GSK plc announced the acquisition of ordinary shares by several key executives under the ...

UK-based big pharma GlaxoSmithKline (GSK) has released its Q2 2025 results, which highlight the varying successes of its current portfolio. While the company’s total sales in this period totalled £8bn ...

In a report released today, Justin Smith from Bernstein maintained a Buy rating on GlaxoSmithKline, with a price target of £21.70. The company’s shares closed today at p1,373.00. Take advantage of ...

A month has gone by since the last earnings report for GSK (GSK). Shares have added about 3.2% in that time frame, underperforming the S&P 500. Will the recent positive trend continue leading up ...

GlaxoSmithKline (GSK) closed at $45.06 in the latest trading session, marking a -0.4% move from the prior day. This change was narrower than the S&P 500's daily loss of 1.42%. At the same time ...

GlaxoSmithKline has picked a familiar face to lead its consumer health business after a planned spinoff next year. Hint: It’s not group CEO Emma Walmsley. Brian McNamara, currently head of GSK ...

GlaxoSmithKline has said it would keep an open mind about how to exit the Pfizer-partnered consumer health joint venture. But a sale at $68 billion apparently isn't an option. GSK has rejected ...

GlaxoSmithKline (LSE:GSK), is undergoing a transformation and the company is expected to split into 2 entities mid 2022. Shareholders had an underwhelming performance in the last 3 years, and the ...

Arab Finance: GlaxoSmithKline Egypt (GSK–Egypt) logged consolidated net profits for controlling interest of EGP 65.060 ...

GlaxoSmithKline's Demerger Plan Has Failed To Excite Investors Jul. 26, 2021 5:15 AM ET GSK plc (GLAXF) Stock, GSK Stock GLAXF, GSK 15 Comments 12 Likes ...

The deal includes a $90 million upfront payment from GSK. GlaxoSmithKline entered into a $180 million collaboration deal with German biopharmaceutical company CureVac to jointly develop a next ...